Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2023
2022
2021
2020
2019
2018
2017
2016
Older
Sep 13, 2021
Proposed issue of securities - NEU
Sep 13, 2021
Placement to accelerate NNZ-2591 across 4 indications
Sep 10, 2021
Notification of investor presentation, 9.00 AEST 13 Sept 21
Sep 09, 2021
Trading Halt
Sep 03, 2021
FDA grants Orphan Drug designation for Prader-Willi syndrome
Sep 01, 2021
Angelman IND and Ethics applications submitted for NNZ-2591
Sep 01, 2021
Trofinetide Rett syndrome clinical trial in girls aged 2-5
Aug 30, 2021
R&D Tax Incentive Advance Overseas Finding Approval
Aug 25, 2021
Half-year shareholder update
Aug 25, 2021
Half Yearly Report and Accounts
Previous
1
2
3
4
5
6
Next
